Browsing by Author Borg, John-Joseph

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 26  next >
Issue DateTitleAuthor(s)
2017-09Biosimilars : drug substance quality issues and their impact on the safety profile of biologicsCilia, Mark; Serracino-Inglott, Anthony; Wirth, Francesca; Borg, John-Joseph
2018-10A comparison of approved indications between regulatory agenciesCamilleri, Matthew; Borg, John-Joseph; Sammut Bartolo, Nicolette; Serracino-Inglott, Anthony
2018-09Comparison of post-authorisation requirements between regulatory agencies for medicinal productsCamilleri, Matthew; Borg, John-Joseph; Sammut Bartolo, Nicolette; Serracino-Inglott, Anthony
2015Could EU herbal monographs contribute to Malta’s treatment armamentarium?Micallef, Benjamin; Attard, Everaldo; Serracino-Inglott, Anthony; Borg, John-Joseph
2019-05Decision-maker perspectives on outcomes studied in leukaemia clinical trials : the response evaluation in leukaemia (REVALEU) study protocolSaid, Dylan; Borg, John-Joseph; Attard Pizzuto, Maresca; Serracino-Inglott, Anthony
2015Designing a national combined reporting form for adverse drug reactions and medication errorsTanti, Amy; Serracino-Inglott, Anthony; Borg, John-Joseph
2018-11Developing safe and effective medicinal products to treat Leber hereditary optic neuropathy. Clinical and regulatory challengesZuccarelli, Marta; Borg, John-Joseph; Serracino-Inglott, Anthony; Vella, Janis
2018-09Emerging patterns in the clinical development of medicines in paediatric oncologyMicallef, Benjamin; Borg, John-Joseph; Sammut Bartolo, Nicolette; Serracino-Inglott, Anthony
2019-09Emerging treatments for Leber hereditary optic neuropathy and retinitis pigmentosaZuccarelli, Marta; Borg, John-Joseph; Vella Szijj, Janis; Serracino-Inglott, Anthony
2021Emerging treatments for Retinitis PigmentosaZuccarelli, Marta; Borg, John-Joseph; Vella Szijj, Janis; Azzopardi, Lilian M.; Serracino-Inglott, Anthony
2015European Union pharmacovigilance capabilities : potential for the new legislationBorg, John-Joseph; Tanti, Amy; Kouvelas, Dimitrios; Lungu, Calin; Pirozynski, Michal; Serracino-Inglott, Anthony; Aislaitner, George
2023An exploratory study of the impact of COVID-19 vaccine spontaneous reporting on masking signal detection in EudraVigilanceMicallef, Benjamin; Dogné, Jean-Michel; Sultana, Janet; Straus, Sabine M. J. M.; Nisticò, Robert; Serracino-Inglott, Anthony; Borg, John-Joseph
2022Improving the data quality of spontaneous ADR reports : a practical example from MaltaZuccarelli, Marta; Micallef, Benjamin; Butler, Dianne; Serracino-Inglott, Anthony; Borg, John-Joseph
2013Medication errors through a national pharmacovigilance database approach : a study for MaltaTanti, Amy; Camilleri, Miriam; Vella Bonanno, Patricia; Borg, John-Joseph
2015Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspectiveBorg, John-Joseph; Anker, Stefan D.; Rosano, Giuseppe; Serracino-Inglott, Anthony; Strasser, Florian
2019-05Opinions of decision-makers on the clinical development and assessment of antineoplastic agentsSaid, Dylan; Borg, John-Joseph; Attard Pizzuto, Maresca; Serracino-Inglott, Anthony
2019Optimising bench science to withstand regulatory scrutinyBorg, John-Joseph; Melchiorri, Daniela; Sepodes, Bruno; Caramella, Carla M.; Tomino, Carlo; Micallef, Benjamin; Serracino-Inglott, Anthony
2019-09Outcomes studied in leukaemia clinical trials : a need for harmonisation?Said, Dylan; Borg, John-Joseph; Attard Pizzuto, Maresca; Serracino-Inglott, Anthony
2018Pharmaceutical issues during the review of European Marketing Authorisation Applications in MaltaChetcuti, Michael; Serracino-Inglott, Anthony; Flores, Gavril; Borg, John-Joseph
2022QT shortening : a proarrhythmic safety surrogate measure or an inappropriate indicator of it?Tanti, Amy; Micallef, Benjamin; Vella Szijj, Janis; Serracino-Inglott, Anthony; Borg, John-Joseph